Citadel Advisors
TXMD icon

Citadel Advisors’s TherapeuticsMD TXMD Stock Holding History

Citadel Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,600
Closed -$2.4K – 15174
2025
Q1 		$2.4K Buy
2,600
+2,200
+550% +$2.19K ﹤0.01% 14041
2024
Q4 		$344 Sell
400
-6,700
-94% -$9.43K ﹤0.01% 14342
2024
Q3 		$11.8K Buy
7,100
+7,000
+7,000% +$12.2K ﹤0.01% 13142
2024
Q2 		$161 Sell
100
-3,100
-97% -$6.26K ﹤0.01% 14082
2024
Q1 		$7.33K Sell
3,200
-3,100
-49% -$7.18K ﹤0.01% 13620
2023
Q4 		$14.2K Sell
6,300
-7,100
-53% -$17.1K ﹤0.01% 12890
2023
Q3 		$40.5K Sell
13,400
-11,300
-46% -$42.8K ﹤0.01% 11984
2023
Q2 		$102K Buy
24,700
+13,300
+117% +$52.2K ﹤0.01% 10908
2023
Q1 		$42.8K Sell
11,400
-18,700
-62% -$89.7K ﹤0.01% 12362
2022
Q4 		$168K Sell
30,100
-1,600
-5% -$9.42K ﹤0.01% 10426
2022
Q3 		$210K Buy
31,700
+17,500
+123% +$142K ﹤0.01% 10312
2022
Q2 		$141K Buy
14,200
+13,720
+2,858% +$131K ﹤0.01% 11051
2022
Q1 		$9K Sell
480
-1,582
-77% -$24.9K ﹤0.01% 13390
2021
Q4 		$37K Buy
2,062
+50
+2% +$1.5K ﹤0.01% 13401
2021
Q3 		$75K Buy
2,012
+30
+2% +$1.33K ﹤0.01% 13112
2021
Q2 		$118K Sell
1,982
-1,716
-46% -$104K ﹤0.01% 12764
2021
Q1 		$248K Buy
3,698
+1,458
+65% +$114K ﹤0.01% 11254
2020
Q4 		$136K Sell
2,240
-152
-6% -$10.4K ﹤0.01% 10007
2020
Q3 		$189K Sell
2,392
-906
-27% -$72.2K ﹤0.01% 8854
2020
Q2 		$206K Buy
3,298
+1,062
+47% +$61.8K ﹤0.01% 8489
2020
Q1 		$119K Sell
2,236
-1,006
-31% -$99.7K ﹤0.01% 8506
2019
Q4 		$392K Buy
3,242
+336
+12% +$48.3K ﹤0.01% 7185
2019
Q3 		$527K Buy
2,906
+472
+19% +$66.5K ﹤0.01% 6647
2019
Q2 		$316K Buy
2,434
+562
+30% +$101K ﹤0.01% 7512
2019
Q1 		$456K Sell
1,872
-262
-12% -$69.3K ﹤0.01% 6941
2018
Q4 		$407K Sell
2,134
-814
-28% -$199K ﹤0.01% 6737
2018
Q3 		$967K Buy
2,948
+606
+26% +$186K ﹤0.01% 5611
2018
Q2 		$731K Sell
2,342
-296
-11% -$90.4K ﹤0.01% 5751
2018
Q1 		$642K Buy
2,638
+806
+44% +$226K ﹤0.01% 5472
2017
Q4 		$553K Buy
1,832
+984
+116% +$274K ﹤0.01% 5501
2017
Q3 		$224K Buy
848
+570
+205% +$165K ﹤0.01% 6525
2017
Q2 		$73K Buy
+278
New +$69.6K ﹤0.01% 7002
2017
Q1 		– Sell
-814
Closed -$235K – 8066
2016
Q4 		$235K Buy
+814
New +$252K ﹤0.01% 6056
2016
Q2 		– Sell
-542
Closed -$173K – 7424
2016
Q1 		$173K Sell
542
-428
-44% -$146K ﹤0.01% 5747
2015
Q4 		$503K Buy
970
+642
+196% +$237K ﹤0.01% 4466
2015
Q3 		$96K Buy
328
+80
+32% +$28.4K ﹤0.01% 6992
2015
Q2 		$97K Buy
248
+104
+72% +$36.7K ﹤0.01% 7105
2015
Q1 		$44K Buy
144
+32
+29% +$7.81K ﹤0.01% 7458
2014
Q4 		$25K Sell
112
-80
-42% -$16.5K ﹤0.01% 7658
2014
Q3 		$45K Buy
192
+154
+405% +$38.8K ﹤0.01% 6963
2014
Q2 		$8K Sell
38
-4
-10% -$890 ﹤0.01% 7633
2014
Q1 		$13K Buy
+42
New +$13.4K ﹤0.01% 7430

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's TXMD Position: Q1 2026 in Review

Citadel Advisors increased its TherapeuticsMD (TXMD) stake by 142% in Q1 2026, buying an estimated $90.1K and bringing the position to 68,314 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #11751.

Citadel Advisors first reported a position in TXMD in Q1 2014 and has held it in 39 quarters since. The position peaked at $18.6M in Q1 2017. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Citadel Advisors held 68,314 shares of TherapeuticsMD worth $138K as of Q1 2026.
  • Citadel Advisors bought 40,074 TherapeuticsMD shares in Q1 2026, an estimated $90.1K.
  • TherapeuticsMD made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11751 holding.
  • Citadel Advisors first reported a position in TherapeuticsMD in Q1 2014 and has held it in 39 quarters since.
  • Citadel Advisors's TherapeuticsMD position peaked at $18.6M in Q1 2017.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.